Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer

Nuclear Medicine and Biology

Volumn 38, Issue 7, 2011, Pages 969-978

  Peterson, Lanell M ^a,b   Kurland, Brenda F ^c   Link, Jeanne M ^a   Schubert, Erin K ^a,b   Stekhova, Svetlana ^a   Linden, Hannah M ^a   Mankoff, David A ^a,b  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b SEATTLE CANCER CARE ALLIANCE   (United States)

^c USA   (United States)

Author keywords

Breast cancer; FES PET; SHBG; Specific activity

Indexed keywords

ESTROGEN RECEPTOR; FLUOROESTRADIOL F 18; RADIOPHARMACEUTICAL AGENT; SEX HORMONE BINDING GLOBULIN; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD ANALYSIS; BODY MASS; BODY WEIGHT; BREAST CANCER; CLINICAL STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG METABOLISM; DRUG TRANSPORT; DRUG UPTAKE; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; LABORATORY DIAGNOSIS; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; MENOPAUSE; POSITRON EMISSION TOMOGRAPHY; PREDICTOR VARIABLE; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; RISK ASSESSMENT; RISK FACTOR; VALIDATION PROCESS;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL TRANSPORT; BODY MASS INDEX; BREAST NEOPLASMS; ESTRADIOL; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, ESTROGEN; SEX FACTORS; SEX HORMONE-BINDING GLOBULIN; YOUNG ADULT;

EID: 79960429381     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2011.03.002     Document Type: Article

References (28)

1. Mintun M.A., Welch M.J., Siegel B.A., et al. Breast cancer: PET imaging of estrogen receptors. Radiology 1988, 169:45-48.
2. Peterson L.M., Mankoff D.A., Lawton T., et al. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. J Nucl Med 2008, 49:367-374.
3. Mankoff D.A., Link J.M., Linden H.M., Sundararajan L., Krohn K.A. Tumor receptor imaging. J Nucl Med 2008, 49(Suppl 2):149S-163S.
4. Key T.J. Serum oestradiol and breast cancer risk. Endocr Relat Cancer 1999, 6:175-180.
5. Zeleniuch-Jacquotte A., Toniolo P., Levitz M., et al. Endogenous estrogens and risk of breast cancer by estrogen receptor status: a prospective study in postmenopausal women. Cancer Epidemiol Biomarkers Prev 1995, 4:857-860.
6. Rossi E., Morabito A., Di Rella F., et al. Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial. J Clin Oncol 2009, 27:3192-3197.
7. Katzenellenbogen J.A. Designing steroid receptor-based radiotracers to image breast and prostate tumors. J Nucl Med 1995, 36:8S-13S.
8. Katzenellenbogen J.A., Welch M.J., Dehdashti F. The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer. Anticancer Res 1997, 17:1573-1576.
9. Mathias C.J., Welch M.J., Katzenellenbogen J.A., et al. Characterization of the uptake of 16 alpha-([18F]fluoro)-17 beta-estradiol in DMBA-induced mammary tumors. Int J Radiat Appl Instrum B 1987, 14:15-25.
10. Mankoff D.A., Tewson T.J., Eary J.F. Analysis of blood clearance and labeled metabolites for the estrogen receptor tracer [F-18]-16 alpha-fluoroestradiol (FES). Nucl Med Biol 1997, 24:341-348.
11. Murad F. Hormones and hormone antagonists 1990, Pergamon Press, New York. 8th ed.
12. Kiesewetter D.O., Kilbourn M.R., Landvatter S.W., Heiman D.F., Katzenellenbogen J.A., Welch M.J. Preparation of four fluorine-18-labeled estrogens and their selective uptakes in target tissues of immature rats. J Nucl Med 1984, 25:1212-1221.
13. Tewson T.J., Mankoff D.A., Peterson L.M., Woo I., Petra P. Interactions of 16alpha-[18F]-fluoroestradiol (FES) with sex steroid binding protein (SBP). Nucl Med Biol 1999, 26:905-913.
14. Jonson S.D., Bonasera T.A., Dehdashti F., Cristel M.E., Katzenellenbogen J.A., Welch M.J. Comparative breast tumor imaging and comparative in vitro metabolism of 16alpha-[18F]fluoroestradiol-17beta and 16beta-[18F]fluoromoxestrol in isolated hepatocytes. Nucl Med Biol 1999, 26:123-130.
15. Katzenellenbogen J.A., Mathias C.J., VanBrocklin H.F., Brodack J.W., Welch M.J. Titration of the in vivo uptake of 16 alpha-[18F]fluoroestradiol by target tissues in the rat: competition by tamoxifen, and implications for quantitating estrogen receptors in vivo and the use of animal models in receptor-binding radiopharmaceutical development. Nucl Med Biol 1993, 20:735-745.
16. Lim J.L., Zheng L., Berridge M.S., Tewson T.J. The use of 3-methoxymethyl-16 beta, 17 beta-epiestriol-O-cyclic sulfone as the precursor in the synthesis of F-18 16 alpha-fluoroestradiol. Nucl Med Biol 1996, 23:911-915.
17. Romer J., Fuchtner F., Steinbach J., Johannsen B. Automated production of 16alpha-[18F]fluoroestradiol for breast cancer imaging. Nucl Med Biol 1999, 26:473-479.
18. Linden H.M., Stekhova S.A., Link J.M., et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 2006, 24:2793-2799.
19. Fattah D.I., Chard T. Simplified method for measuring sex-hormone binding globulin. Clin Chem 1981, 27:1277-1279.
20. Hallynck T.H., Soep H.H., Thomis J.A., Boelaert J., Daneels R., Dettli L. Should clearance be normalised to body surface or to lean body mass?. Br J Clin Pharmacol 1981, 11:523-526.
21. Cleveland W.S. Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc 1979, 74:829-836.
22. Levine D., Bankier A.A., Halpern E.F. Submissions to Radiology: our top 10 list of statistical errors. Radiology 2009, 253:288-290.
23. Fisher L.D., van Belle G. Biostatistics: a methodology for the health sciences 1993, Wiley, New York.
24. Kuukasjarvi T., Kononen J., Helin H., Holli K., Isola J. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 1996, 14:2584-2589.
25. Sugawara Y., Zasadny K.R., Neuhoff A.W., Wahl R.L. Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction. Radiology 1999, 213:521-525.
26. Hryb D.J., Khan M.S., Romas N.A., Rosner W. The control of the interaction of sex hormone-binding globulin with its receptor by steroid hormones. J Biol Chem 1990, 265:6048-6054.
27. Erselcan T., Turgut B., Dogan D., Ozdemir S. Lean body mass-based standardized uptake value, derived from a predictive equation, might be misleading in PET studies. Eur J Nucl Med Mol Imaging 2002, 29:1630-1638.
28. Graham M.M., Peterson L.M., Hayward R.M. Comparison of simplified quantitative analyses of FDG uptake. Nucl Med Biol 2000, 27:647-655.